Neuland Laboratories (NSE:NEULANDLAB) Retained Earnings: ₹13,432 Mil (As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
90 GF Score
Price ₹19,506.00
GF Value ₹16,045.13
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Neuland Laboratories Retained Earnings?

Neuland Laboratories NSE:NEULANDLAB -0.18% 90 Retained Earnings is ₹13,432 Mil as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,045.13 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Neuland Laboratories's retained earnings for the quarter that ended in Mar. 2026 was ₹13,432 Mil.

Neuland Laboratories's quarterly retained earnings stayed the same from Sep. 2025 (₹0 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹13,432 Mil).

Neuland Laboratories's annual retained earnings increased from Mar. 2024 (₹7,525 Mil) to Mar. 2025 (₹9,946 Mil) and increased from Mar. 2025 (₹9,946 Mil) to Mar. 2026 (₹13,432 Mil).


Neuland Laboratories  (NSE:NEULANDLAB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Neuland Laboratories Retained Earnings Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories Retained Earnings Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,081.32 4,652.35 7,524.84 9,946.30 13,432.33

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,946.30 0.00 0.00 0.00 13,432.33
NSE:NEULANDLAB
90GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹13,432 Mil mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Retained Earnings of ₹13,432 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Neuland Laboratories and its competitors.
Is Neuland Laboratories' Retained Earnings too high?
Neuland Laboratories' current Retained Earnings is ₹13,432 Mil. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Retained Earnings compare to ZTS and UTHR?
Neuland Laboratories' Retained Earnings of ₹13,432 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Neuland Laboratories and its competitors. Neuland Laboratories's current Retained Earnings is ₹13,432 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,045.13, compared to a current price of ₹19,506.00 — trading 21.6% above its estimated fair value. The current Retained Earnings is ₹13,432 Mil. Neuland Laboratories' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Retained Earnings is ₹13,432 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹19,506.00 is trading 21.6% above its estimated GF Value™ of ₹16,045.13. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • Retained Earnings: ₹13,432 Mil
  • GF Value™: ₹16,045.13 vs. price of ₹19,506.00 (21.6% above fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score

Get the complete analysis for NSE:NEULANDLAB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹19,506.00
Price
₹16,045.13
GF Value